Skip to main content

Table 2 Age at diagnosis, tamoxifen use, FIGO stage, and interval between tumors, by morphology of endometrial cancer after breast cancer

From: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

  Endometrial cancer morphologya
  Endometrioid carcinomab Serous or clear cellc Carcinosarcomad Sarcomae
  N = 1,580 N = 108 N = 108 N = 54
Age at diagnosis of endometrial cancer (years)
   < 55 165 10.4 4 3.7 8 7.4 12 22.2
   55 to 64 413 26.1 19 17.6 17 15.7 15 27.8
   65 to 74 553 35.0 39 36.1 39 36.1 17 31.5
   75 to 84 363 23.0 34 31.5 33 30.6 9 16.7
   85 and over 86 5.4 12 11.1 11 10.2 1 1.9
   Mean (SD), years 68.9 (10.3) 73.4 (9.4) 71.2 (10.4) 67.6 (9.5)
  analysis of variance (3 d.f.): P < 0.001f
Tamoxifen use         
   Not used 651 41.2 44 40.7 19 17.6 17 31.5
   Used 929 58.8 64 59.3 89 82.4 37 68.5
  Pearson chi-sq (3 d.f.): P < 0.0001g
   Duration of tamoxifen use among users
Used, < 2 years 272 29.3 19 29.7 11 12.4 10 27.0
2 to < 5 years 326 35.1 19 29.7 31 34.8 12 32.4
5 or more years 285 30.7 23 35.9 37 41.6 13 35.1
Used, duration unknown 46 5.0 3 4.7 10 11.2 2 5.4
Mean (SD), years 4.1 (3.2) 4.1 (2.8) 5.2 (3.3) 4.0 (2.8)
  analysis of variance (3 d.f.): P = 0.025g
   Tamoxifen, time since last use among users
Still on/≤ 3 months 649 69.9 34 53.1 50 56.2 24 64.9
3 months to < 1 year 70 7.5 5 7.8 5 5.6 3 8.1
1 year to < 3 years 73 7.9 8 12.5 10 11.2 6 16.2
3 years to < 5 years 35 3.8 6 9.4 7 7.9 2 5.4
5 or more years 56 6.0 8 12.5 8 9.0 0 0.0
Used, time unknown 46 5.0 3 4.7 9 10.1 2 5.1
Mean (SD), years 0.8 (2.0) 1.7 (2.8) 1.3 (2.2) 0.7 (1.3)
  analysis of variance (3 d.f.): P = 0.002g
FIGO stage         
   I 914 57.9 46 42.6 35 32.4 21 38.9
   II 111 7.0 14 13.0 3 2.8 4 7.4
   III/IV 82 5.2 27 25.0 20 18.5 11 20.4
   Unknown 473 29.9 21 19.4 50 46.3 18 33.3
  Peasron chi-sq (9 d.f.): P < 0.001g
Interval between breast and endometrial cancer (years)
   3 to 12 months 102 6.5 8 7.4 3 2.8 2 3.7
   1 to < 3 years 400 25.3 17 15.7 16 14.8 15 27.8
   3 to < 5 years 305 19.3 18 16.7 18 16.7 12 22.2
   5 to < 10 years 508 32.2 47 43.5 46 45.4 21 38.9
   10 to 29 years 265 16.8 18 16.7 22 20.4 4 7.4
   Mean (SD), years 5.9 (4.3) 6.5 (4.1) 6.9 (3.9) 5.2 (3.2)
  analysis of variance (3 d.f.): (P = 0.039)g
Total 1,580 100.0 108 100.0 108 100.0 54 100.0
  1. aExcludes 25 patients where morphology was unknown; bEndometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma; cSerous adenocarcinoma, clear cell adenocarcinoma; dCarcinosarcoma, Mullerian mesodermal mixed tumors; eSarcoma, endometrial stromal adenocarcinoma, leiomyosarcoma; fadjusted for study; gadjusted for age at diagnosis and study. N, number; SD, standard deviation.